Published in Antimicrob Agents Chemother on November 01, 2005
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol (2006) 2.60
Hospital epidemiology and infection control in acute-care settings. Clin Microbiol Rev (2011) 2.22
Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother (2010) 2.02
Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med (2009) 1.86
Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One (2011) 1.73
Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J Clin Microbiol (2007) 1.65
Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother (2010) 1.16
Retracted Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol (2010) 1.16
Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection (2013) 1.14
Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob Agents Chemother (2012) 1.11
Epidemiology, species distribution, antifungal susceptibility, and outcome of candidemia across five sites in Italy and Spain. J Clin Microbiol (2013) 1.10
Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob Agents Chemother (2012) 1.05
Blood stream infections by Candida glabrata and Candida krusei: a single-center experience. Korean J Intern Med (2009) 0.91
Treatment of invasive candidiasis in the elderly: a review. Clin Interv Aging (2013) 0.86
Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility. J Med Microbiol (2012) 0.85
A cluster of Candida krusei infections in a haematological unit. BMC Infect Dis (2007) 0.81
Genome engineering in the yeast pathogen Candida glabrata using the CRISPR-Cas9 system. Sci Rep (2016) 0.80
A single-centre 10-year experience with Candida bloodstream infections. Can J Infect Dis Med Microbiol (2009) 0.79
Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Front Microbiol (2017) 0.75
The effect of cumulative length of hospital stay on the antifungal resistance of Candida strains isolated from critically ill surgical patients. Mycopathologia (2010) 0.75
Concise review: next-generation cell therapies to prevent infections in neutropenic patients. Stem Cells Transl Med (2014) 0.75
Epidemiology of Candida albicans and non-C.albicans of neonatal candidemia at a tertiary care hospital in western China. BMC Infect Dis (2017) 0.75
Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study. Mycopathologia (2017) 0.75
Cross-resistance between voriconazole and fluconazole for non-albicans Candida infection: a case-case-control study. Eur J Clin Microbiol Infect Dis (2017) 0.75
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med (1991) 12.09
Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis (1999) 10.30
Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis (2003) 7.09
The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis (1997) 7.09
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med (1996) 6.49
A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med (1992) 6.06
Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol (2000) 5.38
Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis (1995) 4.35
Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis (2002) 4.35
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med (2004) 4.30
Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. Clin Infect Dis (2001) 3.75
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. J Hosp Infect (2002) 3.63
In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother (2002) 3.36
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother (1993) 3.25
Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med (1989) 2.97
Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol (2002) 2.94
Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med (1993) 2.90
International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis (1997) 2.78
Nosocomial candidemia: risk factors and attributable mortality. Clin Infect Dis (1995) 2.74
A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 2.29
Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis (1995) 2.20
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Has the epidemiology of nosocomial candidemia changed? Infect Control Hosp Epidemiol (2004) 2.04
Increased incidence of fungemia caused by Candida krusei. J Clin Microbiol (1986) 1.82
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg Infect Dis (2002) 1.77
Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.63
Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol (1998) 1.57
Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg (1997) 1.31
Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis (1999) 1.25
The contribution of fluconazole to the changing epidemiology of invasive candidal infections. Clin Infect Dis (1997) 1.23
Risk factors for recovery of ampicillin-sulbactam-resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother (2000) 1.20
Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect (2002) 1.18
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob Agents Chemother (1993) 1.18
Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study. J Antimicrob Chemother (2000) 1.01
Clinical isolation and resistance patterns of and superinfection with 10 nosocomial pathogens after treatment with ceftriaxone versus ampicillin-sulbactam. Antimicrob Agents Chemother (2001) 0.96
Low-dose fluconazole as primary prophylaxis for cryptococcal infection in AIDS patients with CD4 cell counts of < or = 100/mm3: demonstration of efficacy in a positive, multicenter trial. Clin Infect Dis (1996) 0.95
Relative effectiveness of various yeasts, Candida spp. and Torulopsis glabrata, for inducing palatal infection in the Wistar rat. Arch Oral Biol (1983) 0.93
The role of 'confounding by indication' in assessing the effect of quality of care on disease outcomes in general practice: results of a case-control study. BMC Health Serv Res (2005) 0.90
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis (2002) 11.30
Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother (2009) 6.33
The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol (2005) 5.86
Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother (2006) 4.50
Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg Infect Dis (2010) 4.25
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis (2003) 4.06
Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother (2007) 4.03
Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother (2007) 3.74
High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother (2007) 3.62
Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother (2007) 3.55
Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother (2007) 3.44
Clinical and economic impact of bacteremia with extended- spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2006) 3.33
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Consensus review of the epidemiology and appropriate antimicrobial therapy of complicated urinary tract infections in Asia-Pacific region. J Infect (2011) 3.10
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother (2006) 3.09
Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Enterococci, and Escherichia coli. Clin Infect Dis (2002) 2.99
Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA (2008) 2.95
First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother (2008) 2.93
The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis (2003) 2.92
Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA (2004) 2.90
Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis (2011) 2.89
Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol (2007) 2.85
Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke (2007) 2.55
Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis (2005) 2.52
Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother (2008) 2.38
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 2.33
Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis (2005) 2.10
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in hospitalized patients. Emerg Infect Dis (2003) 2.06
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med (2002) 2.00
Complete nucleotide sequence of KPC-3-encoding plasmid pKpQIL in the epidemic Klebsiella pneumoniae sequence type 258. Antimicrob Agents Chemother (2010) 1.97
Impact of quinolone restriction on resistance patterns of Escherichia coli isolated from urine by culture in a community setting. Clin Infect Dis (2009) 1.92
Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis (2004) 1.91
High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother (2005) 1.90
A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med (2011) 1.88
Glycopeptides are no more effective than beta-lactam agents for prevention of surgical site infection after cardiac surgery: a meta-analysis. Clin Infect Dis (2004) 1.87
The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol (2005) 1.77
Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci. Antimicrob Agents Chemother (2002) 1.71
Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. Antimicrob Agents Chemother (2005) 1.67
Rotavirus infection in adults. Lancet Infect Dis (2004) 1.65
Laboratory and clinical evaluation of screening agar plates for detection of carbapenem-resistant Enterobacteriaceae from surveillance rectal swabs. J Clin Microbiol (2011) 1.64
Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg (2007) 1.61
Improved antimicrobial peptides based on acyl-lysine oligomers. Nat Biotechnol (2007) 1.53
Surveillance cultures and duration of carriage of multidrug-resistant Acinetobacter baumannii. J Clin Microbiol (2007) 1.52
Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis (2004) 1.51
Evaluation of PCR-based testing for surveillance of KPC-producing carbapenem-resistant members of the Enterobacteriaceae family. J Clin Microbiol (2009) 1.51
Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel. Antimicrob Agents Chemother (2010) 1.49
Single-cell electroporation. Curr Opin Biotechnol (2003) 1.45
Risk factors for albicans and non-albicans candidemia in the intensive care unit. Crit Care Med (2008) 1.43
Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain. J Antimicrob Chemother (2009) 1.43
Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis (2008) 1.41
The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion. J Urol (2012) 1.41
CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum beta-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother (2005) 1.41
Antibiotic therapy in the demented elderly population: redefining the ethical dilemma. Arch Intern Med (2008) 1.39
Transfer of carbapenem-resistant plasmid from Klebsiella pneumoniae ST258 to Escherichia coli in patient. Emerg Infect Dis (2010) 1.39
Antibacterial properties of dermaseptin S4 derivatives with in vivo activity. Antimicrob Agents Chemother (2002) 1.36
Occurrence and phenotypic characteristics of extended-spectrum beta-lactamases among members of the family Enterobacteriaceae at the Tel-Aviv Medical Center (Israel) and evaluation of diagnostic tests. J Clin Microbiol (2003) 1.35
Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. J Antimicrob Chemother (2010) 1.34
Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci (2014) 1.34
Methicillin-resistant Staphylococcus aureus in neonatal intensive care unit. Emerg Infect Dis (2005) 1.32
Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2006) 1.31
Mechanisms by which antibiotics promote dissemination of resistant pneumococci in human populations. Am J Epidemiol (2005) 1.31
How to stem the tide of carbapenemase-producing enterobacteriaceae?: proactive versus reactive strategies. Curr Opin Infect Dis (2010) 1.30
Two cases of necrotizing fasciitis due to Acinetobacter baumannii. J Clin Microbiol (2008) 1.30
Management of outbreaks of methicillin-resistant Staphylococcus aureus infection in the neonatal intensive care unit: a consensus statement. Infect Control Hosp Epidemiol (2006) 1.30
National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2010) 1.29
Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis (2003) 1.29
Carbapenem-resistant KPC-2-producing Escherichia coli in a Tel Aviv Medical Center, 2005 to 2008. Antimicrob Agents Chemother (2010) 1.28
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother (2013) 1.27
Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infect Control Hosp Epidemiol (2005) 1.27
Ertapenem resistance among extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae isolates. J Clin Microbiol (2009) 1.21
Effect of dexamethasone on gliosis, ischemia, and dopamine extraction during microdialysis sampling in brain tissue. Anal Chem (2011) 1.20
Fabrication of microchannel structures in fluorinated ethylene propylene. Anal Chem (2002) 1.19
Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected? Clin Infect Dis (2009) 1.19
Molecular and epidemiologic study of polyclonal outbreaks of multidrug-resistant Acinetobacter baumannii infection in an Israeli hospital. Infect Control Hosp Epidemiol (2007) 1.14
Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nat Rev Microbiol (2004) 1.13
Clinical implications of varying degrees of vancomycin susceptibility in methicillin-resistant Staphylococcus aureus bacteremia. Emerg Infect Dis (2003) 1.13
Infection of a ventriculoatrial shunt with phenotypically variable Staphylococcus epidermidis masquerading as polymicrobial bacteremia due to various coagulase-negative Staphylococci and Kocuria varians. J Clin Microbiol (2003) 1.12
Targeted decolonization to prevent ICU infections. N Engl J Med (2013) 1.12
Treatment options for multidrug-resistant Acinetobacter species. Drugs (2008) 1.11
Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother (2006) 1.10
An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clin Infect Dis (2013) 1.10
Impact of microdialysis probes on vasculature and dopamine in the rat striatum: a combined fluorescence and voltammetric study. J Neurosci Methods (2008) 1.09
Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel. Infect Control Hosp Epidemiol (2011) 1.09
Vitek 2 automated identification system and Kocuria kristinae. J Clin Microbiol (2005) 1.09
Plasmid-mediated qnrB2 and carbapenemase gene bla(KPC-2) carried on the same plasmid in carbapenem-resistant ciprofloxacin-susceptible Enterobacter cloacae isolates. Antimicrob Agents Chemother (2008) 1.07
The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother (2004) 1.07
Dissemination of the CTX-M-25 family beta-lactamases among Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and identification of the novel enzyme CTX-M-41 in Proteus mirabilis in Israel. J Antimicrob Chemother (2008) 1.05
Analogous oligo-acyl-lysines with distinct antibacterial mechanisms. FASEB J (2008) 1.05
Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. J Antimicrob Chemother (2008) 1.03
Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg (2004) 1.03
Analysis of the performance of a flow reactor for use with microcolumn HPLC. Anal Chem (2004) 1.03
Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. J Antimicrob Chemother (2014) 1.02
Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance. Clin Microbiol Rev (2013) 1.01
Utility of the VITEK 2 Advanced Expert System for identification of extended-spectrum beta-lactamase production in Enterobacter spp. J Clin Microbiol (2006) 1.00
Parental Staphylococcus aureus carriage is associated with staphylococcal carriage in young children. Pediatr Infect Dis J (2009) 0.99
Introduction of OXA-48-producing Enterobacteriaceae to Israeli hospitals by medical tourism. J Antimicrob Chemother (2011) 0.99
Incidence of and preoperative risk factors for Staphylococcus aureus bacteremia and chest wound infection after cardiac surgery. Infect Control Hosp Epidemiol (2009) 0.99
Determination of zeta-potential in rat organotypic hippocampal cultures. Biophys J (2008) 0.99